(secondQuint)Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis.

 A Phase 2, multi-center, randomized, double-blind, placebo-controlled study enrolling subjects with moderate-to-severe psoriasis to investigate the safety and efficacy of LD-aminopterin (AMT) (3 mg (six 0.

5 mg tablets).

 Forty-six subjects will be randomized to one of two parallel treatment arms: LD-AMT (3 mg) or placebo, in a 1:1 ratio.

 The endpoint analysis will include efficacy and safety.

 Randomized subjects will initially enter a 14-week treatment phase, followed by a 6-week post-treatment phase.

.

 Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis@highlight

This study evaluates the treatment of psoriasis with aminopterin.

 Participants will be treated for 14 weeks with either aminopterin or placebo followed.

 The participants will not know if they are being treated with aminopterin or placebo.

